SNDX SYNDAX PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - Positive Trial Results Syndax Pharmaceuticals announced positive results from a clinical trial for revumenib, a treatment for a specific type of leukemia, and will hold a conference call to discuss this on November 12, 2024.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC